The HIVE Community

The Health Innovation Virtual Engagement (HIVE) community supports Canadian dermatologists, allergists, immunologists and others with an interest in urticaria to support collaboration and enhance understanding of this condition.

Latest from HIVE

The Buzz, Issue #6 is now available, featuring five new publications with high clinical relevance for Canadian allergists.

The Buzz Issue #6, August edition, will be sent to all HIVE members by email on Monday, July 26, and can be accessed online here. This edition covers: Seroconversion following vaccination for patients on anti-CD20 therapy Association between meconium metabolome and atopy in Canadian infants Context for a network meta-analysis of antihistamines in chronic spontaneous … Continue reading The Buzz, Issue #6 is now available, featuring five new publications with high clinical relevance for Canadian allergists.

The Buzz, Issue #5 is now available! In this issue, we highlight new publications in urticaria, angioedema, asthma and draw attention to the new food allergy guidelines for childcare centres and schools.

The Buzz Issue #5, July edition, was sent to all HIVE members by email on Monday, June 28, and can be accessed online here. This edition covers: Urticaria disease activity during and after pregnancy A practical approach to identifying angioedema and urticaria mimics Conditional recommendations on the prevention and management of allergic reactions in schools … Continue reading The Buzz, Issue #5 is now available! In this issue, we highlight new publications in urticaria, angioedema, asthma and draw attention to the new food allergy guidelines for childcare centres and schools.

The Buzz, Issue #4 is now available! In this issue, we have five new articles to bring to the attention of Canadian allergists.

The Buzz Issue #4, June edition, was sent to all HIVE members by email on Monday, May 31, and can be accessed online here. This edition covers: Pathogenic differentiation of CHA and CSU Considerations for proceeding with or delaying the COViD-19 mRNA vaccine booster following a suspected anaphylactic event Case reports of omalizumab exposure in … Continue reading The Buzz, Issue #4 is now available! In this issue, we have five new articles to bring to the attention of Canadian allergists.